Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

Germany's Merck sees boost from labs supplies earnings

Pfizer

England's drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA's (OTCMKTS: MKGAF) Bavencio (avelumab) as first-line maintenance therapy for urothelial cancer after platinum-based chemo. The PD-L1 inhibitor, therefore, won't be able to enjoy routine NHS reimbursement or coverage through the more complicated and restrictive Cancer Drugs Fund, said the National Institute for Health and Care Excellence (NICE).

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer

AbbVie

Chevron

Marsh & McLennan

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Bristol-Myers

GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought.

Guess Which Stocks Warren Buffett Bought: 1st-Quarter Contest

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck Declares Record Date and Dividend for the Organon & Co. Spinoff

Merck Declares Record Date and Dividend for the Organon & Co. Spinoff

Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R). The planned Phase 1/2 combination trial will evaluate the safety, tolerability, and pharmacokinetics of FPI-1434 in combination with pembrolizumab.

Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Receive Priority Review From FDA for KEYTRUDA Plus LENVIMA Applications for Advanced RCC and for Advanced Endometrial Carcinoma

Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma

Advanced Micro Devices

GlaxoSmithKline

Pinterest

Zoom Video

These very well-known companies could put some serious green in your pocket over the next 12 months.

5 Brand-Name Stocks With 27% to 50% Upside, According to Wall Street

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy for 1L Treatment of HER2-Positive Gastric or GEJ Adenocarcinoma

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

CVS Health

SSR Mining

Bargains abound for patient long-term investors.

3 Value Stocks That'll Make You Richer in May (and Beyond)

German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.

German labs supplier Merck raises forecast on strong first quarter

The investors weren't happy with Merck's Q1 performance and the stock declined over 4% in a single trading session, post the earnings announcement. Now that half of the U.S. population has received at least one dose of vaccine, the economy is expected to open up gradually, boding well for Merck.

What's Next For Merck Stock After A 5% Drop Following Q1 Miss?

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck Hosts Organon Investor Day Outlining New Company's Vision, Focus and Business Model for Sustained Growth.

Merck Hosts Organon Investor Day Outlining New Company's Vision, Focus and Business Model for Sustained Growth

Lockheed Martin

The S&P 500 is likely to hold up into the 6th, but the market is likely to be lower by the end of May.

Stocks This Week: Sell Short Lockheed Martin And Merck

Which company should you consider buying right now?

Better Buy for 2021: AbbVie or Merck?

Johnson & Johnson

These two blue-chip pharmaceuticals pay great dividends.

2 Top Stocks for 2021 and Beyond

Investors were not impressed with the company's latest quarterly update.

Why Merck Stock Dropped Today

AstraZeneca

In my April 27 discussion, I looked at the pharmaceutical companies that are most likely to pursue acquisitions this year, with activity forecasted to pick up after a down 2020. While the pandemic contributed to the slowdown in merger and acquisitions, licensing arrangements fared far better, coming in relatively flat at a total value of about $40 billion

AstraZeneca, Merck, AbbVie Struck Biggest Licensing Deals in 2020

Merck & Co (NYSE:MRK) shares are trading lower after the company reported worse-than-expected EPS and sales results. Merck reported quarterly earnings of $1.40 per share, which missed the analyst consensus estimate of $1.63.

Why Is Merck's Stock Trading Lower Today?

Merck & Co, Inc. (MRK) CEO Ken Frazier on Q1 2021 Results - Earnings Call Transcript

Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.

Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines

Roche Holding AG

The FDA's Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co's (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval alive as a first-line bladder cancer treatment, even after a Merck confirmatory trial failed. While the confirmatory trial did not show a benefit for Keytruda as a first-line treatment, much of the discussion centered on these subgroups of patients who might have no treatment options without Keytruda.

Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer

The big drugmaker's declining vaccine sales were the biggest problem.

What's Behind Merck's Q1 Earnings Miss

Merck stock tumbled Thursday as the coronavirus pandemic contributed to a sluggish first quarter, though the company's 2021 outlook remained strong in relation to analysts' forecasts. The post Merck Stock Dives As Pandemic Bungles First-Quarter Sales, Earnings appeared first on Investor's Business Daily.

Merck Stock Dives As Pandemic Bungles First-Quarter Sales, Earnings

Merck (MRK) delivered earnings and revenue surprises of -14.11% and -5.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Merck Stock (MRK)